Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
Ontology highlight
ABSTRACT: Fabry disease (FD) is an uncommon, X-linked, lysosomal storage disease that causes defects in the glycosphingolipid metabolic pathway due to deficient or absent lysosomal α-galactosidase (α-Gal A) activity. This leads to the accumulation of globotriaosylceramide (GL-3) within lysosomes in a wide range of cells, including endothelial, cardiac, renal, and corneal cells, and consequently, the progressive appearance of clinical symptoms in target organs. Enzyme replacement therapy (ERT), which involves the exogenous supplementation of α-Gal A enzyme and has been successfully administered for treating FD.Here, we report a case of a 37-year-old male with complaints of recurrent proteinuria and ventricular septal thickening. A renal biopsy revealed vacuolization and foamy changes in podocytes, an
SUBMITTER: Chen Z
PROVIDER: S-EPMC10882756 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA